Back to News
Market Impact: 0.2
Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Rothschild & Co upgraded Abbott Laboratories (NYSE: ABT) to Buy from Neutral on October 2, 2026. The upgrade is a positive analyst signal for the global healthcare company, though the article provides no price target, earnings estimates, or underlying rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ABT0.55
More News
- Jim Cramer's top 10 things to watch in the stock market Friday
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)